Trial Profile
Retrospective study evaluating the safety and efficacy of Nivolumab in treatment of relapsed or refractory Hodgkin's Lymphoma after allogenic hematopoietic cell transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2016 New trial record
- 08 Dec 2015 Preliminary results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology